The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Louise.Dinnett@glasgow.ac.uk
Clinical Trials Unit, Coap, West Scotland Cancer Centre, Gartnaval Hospital Glasgow G11
Estcourt, L. J. et al. (2025) Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial. Lancet Haematology, 12(1), e14-e22. (doi: 10.1016/S2352-3026(24)00317-X) (PMID:39642900)
Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)
Estcourt, L. J. et al. (2025) Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial. Lancet Haematology, 12(1), e14-e22. (doi: 10.1016/S2352-3026(24)00317-X) (PMID:39642900)
Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)